

Bakers Union and FELRA Health and Welfare Fund

Quarterly Review
January – June 2023

September 13, 2023



Today's Topics

1. Key Discussion Topics
2. Performance Summary
3. Trend
4. Top Disease States
5. Rebates
6. Outcomes
 - Clinical Outcomes
 - Vigilant Outcomes
 - VCS Outcomes
7. Drug Pipeline

Your OptumRx Team

Paul Marcus

VP, Client Management
Labor & Trust

Holly Agoney

Strategic Account Executive
Labor & Trust

Caroline Atwood

Director, Client
Management
Labor & Trust

Autumn Leblanc

Pharmacy Account
Manager
Labor & Trust

Fabian Gonzales

Pharmacy Service
Specialist
Labor & Trust

Current Plan Design

☐ Deductible, Ben Max, MOOP, Copays

Plan 1 (group BFWRX):	
Deductible:	This plan has no deductible.
Benefit Maximum:	\$2,000 per year for Growth Hormones medications only
Max out of Pocket:	\$2,850 Individual / \$5,700 Family

Plan 2 (group BFWRX2) & Plan 3 (group BFWRX3):	
Deductible:	This plan has no deductible.
Benefit Maximum:	\$2,000 per year for Growth Hormones medications only
Max out of Pocket:	\$1,850 Individual / \$3,700 Family

Co-pays			
Plan 1 (group BFWRX) & Plan 2 (group BFWRX2):			
	Retail		Mail
*Generic:	\$10	*Generic:	\$20
*Brand:	\$15	*Brand:	\$30
*NP Brand:	\$30	*NP Brand:	\$60
*Specialty:	Run trial claim for co-pay		*Specialty: N/A

Plan 3 (group BFWRX3):		
Retail / Mail		
*Generic:	5%	(\$5 min.)
*Brand:	15%	(\$15 min.)
*NP Brand:	25%	(\$25 min.)
*Specialty:	Run trial claim for co-pay	

☐ Effective 7/1/19

- ☐ Diabetes Program
- ☐ Comprehensive Ums
- ☐ Vigilant Program
- ☐ RxOTC Program

☐ Effective 8/1/2020

- ☐ Orphan Drug Program

☐ Effective 3/1/2021

- ☐ Opioid Mgmt – tighter refill window & UMs

☐ Effective 7/1/2021

- ☐ Premium Formulary
- ☐ Mandatory Mail (MSS)

☐ Effective 1/1/2022

- ☐ Split-fill/Smart-fill

☐ Effective 3/1/2022

- ☐ CCAA/VCS

☐ Effective 5/15/23

- ☐ Price Edge

Key Discussion Topics

- ❑ Per Member Per Month (PMPM) trend = 44.7% Specialty trend = 221.3%
- ❑ Specialty represents 1.3% of claims

- ❑ Top 5 disease states accounted for 75% of total plan paid
 - ❑ Top traditional disease state: Diabetes
 - ❑ Top specialty disease state: Inflammatory Conditions


- ❑ Rebates – January – June 2023
 - ❑ Estimated - \$98,900

- ❑ Clinical Outcomes savings
 - ❑ **UM (PA, ST, QL)** – July 2022 – June 2023
 - ❑ Savings = \$159,600
 - ❑ **Vigilant** – July 2022 – June 2023
 - ❑ Savings = \$11,096
 - ❑ **VCS** – January – June 2023
 - ❑ Savings = \$8,664

Key Statistics

Key Statistics – Performance Summary

Client totals



The key metrics here help highlight the changes Bakers Union and FELRA Health and Welfare Fund has experienced period over period.

- Eligibility has decreased by -41.
- Number of utilizers has decreased by -29.

Total Rx's

CURRENT

3,475

PREVIOUS

3,972

PERCENT CHANGE

-12.5%

Total plan paid

CURRENT

\$580,707

PREVIOUS

\$429,543

PERCENT CHANGE

35.2%

Utilizers

CURRENT

363

PREVIOUS

392

PERCENT CHANGE

-7.4%

Key Statistics

Key statistics with benchmark comparison

Benchmark comparison 1

LABOR AND TRUST

Benchmark comparison 2

COMMERCIAL


Comparing metrics to benchmarks help showcase areas of focus.

- Client trend was 44.7%, compared to the benchmark trend of 13.0%
- Member Paid Share changed by -20.2% period over period, compared to the benchmark of -9.3%

Key statistics	Curr	Prev	Percent change	Curr	Percent change	Curr	Percent change
Average age	43.9	42.9	2.4%	36.9	0.2%	36.8	0.2%
Plan paid PMPM	\$165.21	\$114.15	44.7%	\$126.34	13.0%	\$127.21	15.4%
Plan paid per Rx	\$167.11	\$108.14	54.5%	\$184.80	12.8%	\$162.94	15.9%
Rxs PMPM	0.989	1.056	-6.3%	0.684	0.2%	0.781	-0.4%
Average days supply	30.8	29.1	5.6%	42.6	0.7%	40.3	2.6%
Days supply PMPM	30.4	30.8	-1.1%	29.1	0.9%	31.5	2.2%
Member paid share	7.6%	9.6%	-20.2%	8.3%	-9.3%	12.9%	-7.6%
Member paid per Rx	\$13.79	\$11.42	20.7%	\$16.66	1.4%	\$24.19	5.7%
Generic dispensing rate	85.0%	82.9%	2.6%	87.8%	2.2%	87.4%	1.6%
GDR-without Vaccines	86.4%	86.7%	-0.4%	88.3%	-0.3%	88.1%	-0.6%
Home delivery rate	6.0%	4.4%	36.4%	9.3%	-3.7%	5.2%	1.5%
Retail 90 rate	1.8%	1.2%	44.6%	21.0%	0.9%	20.5%	5.3%
Percent of specialty plan paid	44.3%	19.9%	122.0%	47.2%	0.3%	51.5%	-0.4%

Specialty Key Statistics

Client totals



The key metrics here help highlight the changes Bakers Union and FELRA Health and Welfare Fund has experienced period over period.

- Eligibility has decreased by -41.
- Number of utilizers has increased by 4.

Total Rxs

CURRENT

45

PREVIOUS

36

PERCENT CHANGE

25.0%

Total plan paid

CURRENT

\$257,019

PREVIOUS

\$85,631

PERCENT CHANGE

200.1%

Utilizers

CURRENT

9

PREVIOUS

5

PERCENT CHANGE

80.0%

Specialty Key Statistics

Key statistics with benchmark comparison

Benchmark comparison 1

LABOR AND TRUST

Benchmark comparison 2

COMMERCIAL

Comparing metrics to benchmarks help showcase areas of focus.

- Client trend was 221.3%, compared to the benchmark trend of 13.3%
- Member Paid Share changed by -30.9% period over period, compared to the benchmark of -19.3%

Key statistics	Curr	Prev	Percent change	Curr	Percent change	Curr	Percent change
Plan Paid PMPM	\$73.12	\$22.76	221.3%	\$59.62	13.3%	\$65.55	14.9%
Plan paid per Rx	\$5,711.54	\$2,378.64	140.1%	\$6,434.71	5.7%	\$6,174.15	7.2%
Rxs PMPM	0.013	0.010	33.8%	0.009	7.1%	0.011	7.2%
Average days supply	43.6	29.0	50.5%	33.2	0.6%	32.2	0.9%
Days supply PMPM	0.6	0.3	101.4%	0.3	7.8%	0.3	8.2%
Member paid share	3.4%	4.9%	-30.9%	4.7%	-19.3%	7.2%	-16.0%
Member paid per Rx	\$201.53	\$123.36	63.4%	\$314.66	-15.7%	\$478.37	-11.4%
Generic dispensing rate	20.0%	50.0%	-60.0%	21.3%	-0.7%	21.7%	-3.0%
Home delivery rate	2.2%	2.8%	-20.0%	5.8%	3.5%	4.2%	3.5%
Retail 90 rate	22.2%	0.0%	0.0%	6.7%	0.7%	5.7%	4.8%


Trend Summary

Trend Summary

Trend

Plan paid PMPM has increased 44.7% over the previous period driven primarily by cost in traditional and utilization for specialty.

Specialty represents 1.3% of claims.



+31.8% over benchmark



-11.9% under benchmark




+208.1% over benchmark

Traditional vs. Specialty Trend Components

Traditional trend: 0.8%

Benchmark comparison: LABOR AND TRUST


- Traditional trend contributed 1.4% to the overall trend (44.7%)
- Traditional accounts for 55.7% of overall total plan paid and was down from 80.1% in the prior period



Specialty trend: 221.3%

Benchmark comparison: LABOR AND TRUST

- Specialty trend contributed 98.6% to the overall trend (44.7%)
- Specialty accounts for 44.3% of overall total plan paid and was up from 19.9% in the prior period



Top Disease States & Top 20 Drugs

Top Disease States



Top 5 disease states account for 75% of total Plan Paid

- Inflammatory Conditions accounts for 28.5% of total plan paid, with trend driven by Utilization. DUPIXENT was the top drug
- Diabetes accounts for 26.4% of total plan paid, with trend driven by Drug Mix. JARDIANCE was the top drug

Sort by: Plan Paid

Inflammatory Conditions ▲

PMPM	Trend
\$47.01	118.8%
Top driver: Utilization	

Diabetes ▲

PMPM	Trend
\$43.62	46.6%
Top driver: Drug Mix	

Oncology ▲

PMPM	Trend
\$18.76	4,669.3%
Top driver: Drug Mix	

Cardiovascular ▼

PMPM	Trend
\$7.88	-2.6%
Top driver: Drug Mix	

Asthma / COPD ▼

PMPM	Trend
\$6.62	-50.9%
Top driver: Utilization	

All other ▲

PMPM	Trend
\$41.31	0.9%

Top 20 Drugs by Plan Cost

Specialty

All meds are Brands except indicated with a "G" for generic

Rank														Trend components		
Cu ↑	Pv ↓	Bench ↓	Drug name ↓	Therapy class ↓	Utilizr ↓	Rxs ↓	Avg days supply ↓	Total plan paid ↓	Plan paid per Rx ↓	Curr plan paid PMPM ↓	Prev plan paid PMPM ↓	Bench plan paid PMPM ↓	% Trend ↓	Top driver ↓	% Top driver ↓	
1	1	6	DUPIXENT	Chronic Inflammatory Disease	3	20	28.0	\$65,361	\$3,268.03	\$18.59	\$10.44	\$3.08	78.1%	Utilizr	78.4%	
2	2	1	HUMIRA PEN	Chronic Inflammatory Disease	1	6	28.0	\$42,775	\$7,129.14	\$12.17	\$10.00	\$8.86	21.7%	Cost	9.4%	
3	-	7	SKYRIZI PEN	Chronic Inflammatory Disease	1	2	29.0	\$40,702	\$20,351.12	\$11.58	\$0.00	\$2.62	-	-	-	
4	-	97	KISQALI	Oncology	1	2	28.0	\$33,769	\$16,884.35	\$9.61	\$0.00	\$0.22	-	-	-	
5	-	31	IBRANCE	Oncology	1	2	28.0	\$31,090	\$15,545.22	\$8.85	\$0.00	\$0.71	-	-	-	
6	-	419	TRIPTODUR	LHRH/GNRH Agonist/Antagonists	1	1	168.0	\$19,771	\$19,770.81	\$5.62	\$0.00	\$0.03	-	-	-	
7	8	4	JARDIANCE	★ SGLT-2 Inhibitors & Combos	7	28	36.4	\$18,375	\$656.27	\$5.23	\$3.12	\$3.59	67.4%	Utilizr	58.3%	
8	7	5	TRULICITY	★ GLP-1 Receptor Agonists	5	21	28.4	\$17,846	\$849.79	\$5.08	\$3.17	\$3.37	60.1%	Utilizr	51.9%	
9	20	2	OZEMPIC	★ GLP-1 Receptor Agonists	4	9	59.8	\$16,155	\$1,795.02	\$4.60	\$1.28	\$5.47	258.9%	Utilizr	242.8%	
10	6	51	VICTOZA	★ GLP-1 Receptor Agonists	2	8	45.0	\$12,621	\$1,577.61	\$3.59	\$3.78	\$0.44	-5.0%	Utilizr	-8.2%	
11	-	10	MOUNJARO	★ GLP-1 Receptor Agonists	3	11	28.4	\$10,355	\$941.37	\$2.95	\$0.00	\$2.08	-	-	-	
12	25	18	OTEZLA	Chronic Inflammatory Disease	1	2	30.0	\$9,465	\$4,732.70	\$2.69	\$1.05	\$1.28	157.2%	Cost	157.2%	
13	9	42	JANUMET	★ DPP-4 Inhibitors & Combos	3	15	34.0	\$8,829	\$588.60	\$2.51	\$2.45	\$0.51	2.4%	Cost	5.9%	
14	15	14	JANUVIA	★ DPP-4 Inhibitors & Combos	3	15	30.0	\$7,561	\$504.07	\$2.15	\$1.72	\$1.54	25.1%	Utilizr	23.5%	
15	12	26	ENTRESTO	★ Angiotensin II Receptor & Neprilysin Inhibitor (ARNI)	2	8	45.0	\$7,538	\$942.30	\$2.14	\$2.04	\$0.90	5.4%	Cost	7.6%	
16	-	11	TALTZ	Chronic Inflammatory Disease	1	1	28.0	\$6,940	\$6,940.24	\$1.97	\$0.00	\$2.02	-	-	-	
17	18	19	LANTUS SOLOSTAR	★ Insulin	10	19	36.3	\$6,562	\$345.39	\$1.87	\$1.54	\$1.22	21.0%	Utilizr	64.2%	
18	41	24	HUMALOG KWIKPEN	★ Insulin	6	14	25.9	\$6,149	\$439.24	\$1.75	\$0.58	\$0.96	201.5%	Utilizr	210.9%	
19	31	13	FARXIGA	★ SGLT-2 Inhibitors & Combos	3	11	30.0	\$5,954	\$541.31	\$1.69	\$0.84	\$1.67	102.7%	Utilizr	96.3%	
20	17	8	ELIQUIS	Oral Anticoagulants	3	11	30.0	\$5,698	\$518.02	\$1.62	\$1.56	\$2.50	3.8%	Cost	7.4%	
Total					39	206	34.0	\$373,518	\$1,813.19	\$106.26	\$43.57	\$43.08	143.9%		60.9%	
Plan Total					363	3,475	30.8	\$580,707	\$167.11	\$165.21	\$114.15	\$126.34	44.7%		40.1%	

Rebates


Rebate Performance Summary

Bakers Union and FELRA Health and Welfare Fund

Outcomes date range: Jan - Jun 2023

Benchmark: LABOR AND TRUST

Current rebate value: \$28.13 PMPM



Rebate impact on Plan Paid PMPM

Managing drug spend to a lowest net cost PMPM is achieved through adoption of high performing formulary strategies and driving to lowest net cost products when clinically appropriate. Bakers Union and FELRA Health and Welfare Fund's members adherence to the formulary has earned an offset on PMPM costs, yielding a net plan paid PMPM of \$137.08, versus plan paid PMPM of \$165.21.

Net financial PMPM performance

	Drug cost	Member Paid	Plan Paid	Rebates	Net plan paid
Traditional	\$103.11	\$11.05	\$92.09	\$19.09	\$73.00
Specialty	\$75.70	\$2.58	\$73.12	\$9.04	\$64.08
Total	\$178.82	\$13.63	\$165.21	\$28.13	\$137.08

Total estimated rebate yield for reporting period: \$98.9K

Rebate Performance by Disease State

Disease	Drug cost PMPM	Member paid PMPM	Plan paid PMPM	Rebates PMPM	Net plan paid PMPM	Rebate offset
Diabetes	\$46.36	\$2.74	\$43.62	\$10.72	\$32.90	24.6%
Inflammatory Conditions	\$49.53	\$2.52	\$47.01	\$7.78	\$39.24	16.5%
Asthma / COPD	\$7.02	\$0.40	\$6.62	\$2.40	\$4.22	36.2%
Cardiovascular	\$9.87	\$1.99	\$7.88	\$1.33	\$6.55	16.9%
Oncology	\$18.81	\$0.05	\$18.76	\$1.00	\$17.76	5.4%
Diabetic Supplies	\$2.70	\$0.17	\$2.53	\$0.94	\$1.59	37.1%
Blood Clot Prevention/Stroke Prevention	\$3.00	\$0.16	\$2.84	\$0.86	\$1.99	30.1%
Gastrointestinal, Misc	\$1.37	\$0.07	\$1.30	\$0.37	\$0.93	28.6%
HIV	\$4.28	\$0.56	\$3.71	\$0.33	\$3.38	9.0%
Overactive Bladder / Incontinence	\$1.06	\$0.05	\$1.02	\$0.28	\$0.73	28.0%
Male And Female Hormone Replacement	\$0.97	\$0.08	\$0.90	\$0.28	\$0.61	31.5%
Endocrine And Metabolic	\$5.87	\$0.02	\$5.86	\$0.26	\$5.60	4.4%
Contraception	\$1.39	\$0.04	\$1.34	\$0.24	\$1.11	17.6%
Glaucoma	\$1.07	\$0.09	\$0.98	\$0.19	\$0.79	19.2%
Kidney Disease	\$1.16	\$0.03	\$1.12	\$0.19	\$0.93	16.7%
Weight Loss	\$1.51	\$0.02	\$1.49	\$0.19	\$1.30	12.6%
Ophthalmic Agents	\$0.58	\$0.11	\$0.47	\$0.15	\$0.33	30.8%
Cholesterol Lowering Agents	\$3.56	\$1.09	\$2.47	\$0.11	\$2.35	4.6%
IV/SC/IM Administration Supplies	\$0.25	\$0.11	\$0.14	\$0.10	\$0.04	69.2%
Compounds	\$0.00	\$0.00	\$0.00	\$0.10	\$0.00	0.0%
Migraine/Pain Relief	\$0.55	\$0.08	\$0.47	\$0.09	\$0.37	20.1%
Anti-Inflammatory (Steroids)	\$0.11	\$0.07	\$0.04	\$0.05	\$0.00	108.8%
ADHD & Narcolepsy	\$0.06	\$0.00	\$0.06	\$0.05	\$0.01	84.6%
Antipsychotics	\$0.62	\$0.04	\$0.58	\$0.05	\$0.53	7.9%
Antibiotics	\$1.41	\$0.31	\$1.10	\$0.05	\$1.06	4.1%
Misc Skin Condition	\$1.84	\$0.21	\$1.63	\$0.05	\$1.58	2.8%

Clinical Outcomes

UM Outcomes


Bakers Union and FELRA Health and Welfare Fund

Outcomes date range: Jul 2022 - Jun 2023

Utilization management savings: \$22.24 PMPM

Your program savings: **\$159.6K**

Ensuring patients meet appropriate clinical criteria when initiating medication therapy not only helps to ensure that the patient is being treated safely according to guidelines, but also drives significant savings for both Bakers Union and FELRA Health and Welfare Fund and for members. Bakers Union and FELRA Health and Welfare Fund has realized over \$159.6K in savings. Based on a study by OptumRx, leveraging UM strategies that drive members to appropriate and often lower cost medications for treatment can save a member up to \$620 annually in out of pocket copayments.



Prior authorization

PMPM SAVINGS

\$11.01

NUMBER OF MEMBERS IMPACTED

44

NUMBER OF INTERVENTIONS

54

Quantity limits

PMPM SAVINGS

\$7.23

NUMBER OF MEMBERS IMPACTED

6

NUMBER OF INTERVENTIONS

6

Step therapy

PMPM SAVINGS

\$4.00

NUMBER OF MEMBERS IMPACTED

76

NUMBER OF INTERVENTIONS

86

QL savings is based only on Maximum Daily Dose edits.

Vigilant Outcomes

Bakers Union and FELRA Health and Welfare Fund

Outcomes date range: Jul 2022 - Jun 2023

Total program savings: \$1.55 PMPM

Vigilant Drug Outcomes – Cost Avoidance

By leveraging the Vigilant Drug Program, Bakers Union and FELRA Health and Welfare Fund has:

- Avoided \$11.1K in pharmacy spend
- Switched 9 claims to lower cost alternatives
- 10 claims were abandoned



TOTAL PLAN PAID SAVINGS

\$11,096

TOTAL PROGRAM SAVINGS

0.9%

TOTAL MEMBERS IMPACTED

20

Savings by Vigilant Drug List

Sort by: Members impacted

Vigilant drug list	PMPM savings	Members impacted	Interventions
High Cost Generics	\$1.12	12	12
Clinical Duplicates	\$0.16	4	4
Creams & Patches	\$0.03	1	1
High Cost Brands with Generics	-\$0.02	1	1
New Drugs to Market	\$0.20	1	1
Non-FDA Approved Drugs	\$0.05	1	1

VCS (variable copay solutions) Outcomes

Total program savings: \$2.46 PMPM

Variable copay program savings outcomes

With the OptumRx Variable Copay program, Bakers Union and FELRA Health and Welfare Fund has realized:

- \$8,664 in Plan Paid savings
- \$1,083.00 average Plan Paid per impacted prescription
- 3 total impacted utilizers

PLAN PAID SAVINGS

\$8,664

PLAN PAID SAVINGS PER IMPACTED RX


\$1,083.00

Top 5 drugs based on: Plan paid savings

DUPIXENT
IMPACTED RXS
8
IMPACTED UTILIZERS
3
PLAN PAID SAVINGS
\$8,664

Drug Pipeline

Selected generic launches in 2023 and early 2024



2022 US Sales

Blockbuster drug
(>\$1B in annual U.S. sales)

****Fund has Utilization in Drugs in Red****


[†] Generic has 180-days of exclusivity
ADHD = Attention deficit hyperactivity disorder
COPD = Chronic obstructive pulmonary disease

Current and future biosimilar landscape

Early biosimilars are IV products; pipeline focuses more on self-injection products

Currently available	Brand	Herceptin	Rituxan	Avastin	Neupogen	Epogen / Procrit	Neulasta	Remicade*	Lantus†	Lucentis†	Humira†
	Year 1st entry	2019	2019	2019	2015	2018	2018	2016	2021	2022	2023
	Number of Biosimilar Products Launched	5	3	4	3	1	6	4	3	2	8
	Route of Administration				 						

Biosimilar pipeline (and 2022 US sales)




Appendix

Trend Components

Total trend: 44.7%

Benchmark comparison: LABOR AND TRUST

- Bakers Union and FELRA Health and Welfare Fund's overall trend of 44.7% was 31.8% higher than benchmark
- Specialty spend influenced the trend contributing 98.6% (50.5% higher than benchmark)
- Traditional trend contributed 1.4% (50.5% lower than benchmark)



Top 20 traditional

All meds are Brands

Rank													Trend components		
Cu	Pv	Bench	Drug name	Therapy class	Utilizr	Rxs	Avg days supply	Total plan paid	Plan paid per Rx	Curr plan paid PMPM	Prev plan paid PMPM	Bench plan paid PMPM	% Trend	Top driver	% Top driver
1	6	2	JARDIANCE	SGLT-2 Inhibitors & Combos	7	28	36.4	\$18,375	\$656.27	\$5.23	\$3.12	\$3.59	67.4%	Utilzn	58.3%
2	5	3	TRULICITY	GLP-1 Receptor Agonists	5	21	28.4	\$17,846	\$849.79	\$5.08	\$3.17	\$3.37	60.1%	Utilzn	51.9%
3	18	1	OZEMPIC	GLP-1 Receptor Agonists	4	9	59.8	\$16,155	\$1,795.02	\$4.60	\$1.28	\$5.47	258.9%	Utilzn	242.8%
4	4	25	VICTOZA	GLP-1 Receptor Agonists	2	8	45.0	\$12,621	\$1,577.61	\$3.59	\$3.78	\$0.44	-5.0%	Utilzn	-8.2%
5	-	6	MOUNJARO	GLP-1 Receptor Agonists	3	11	28.4	\$10,355	\$941.37	\$2.95	\$0.00	\$2.08	-	-	-
6	7	22	JANUMET	DPP-4 Inhibitors & Combos	3	15	34.0	\$8,829	\$588.60	\$2.51	\$2.45	\$0.51	2.4%	Cost	5.9%
7	13	8	JANUVIA	DPP-4 Inhibitors & Combos	3	15	30.0	\$7,561	\$504.07	\$2.15	\$1.72	\$1.54	25.1%	Utilzn	23.5%
8	10	15	ENTRESTO	Angiotensin II Receptor & Neprilysin Inhibitor (ARNI)	2	8	45.0	\$7,538	\$942.30	\$2.14	\$2.04	\$0.90	5.4%	Cost	7.6%
9	16	10	LANTUS SOLOSTAR	Insulin	10	19	36.3	\$6,562	\$345.39	\$1.87	\$1.54	\$1.22	21.0%	Utilzn	64.2%
10	37	13	HUMALOG KWIKPEN	Insulin	6	14	25.9	\$6,149	\$439.24	\$1.75	\$0.58	\$0.96	201.5%	Utilzn	210.9%
11	28	7	FARXIGA	SGLT-2 Inhibitors & Combos	3	11	30.0	\$5,954	\$541.31	\$1.69	\$0.84	\$1.67	102.7%	Utilzn	96.3%
12	15	4	ELIQUIS	Oral Anticoagulants	3	11	30.0	\$5,698	\$518.02	\$1.62	\$1.56	\$2.50	3.8%	Cost	7.4%
13	2	5	BIKTARVY	HIV-Multiclass Combo	1	2	30.0	\$5,620	\$2,809.85	\$1.60	\$4.27	\$2.10	-62.5%	Utilzn	-57.2%
14	26	68	NOVOLOG FLEXPEN	Insulin	4	9	34.4	\$5,326	\$591.75	\$1.52	\$0.94	\$0.17	61.9%	Utilzn	44.3%
15	-	9	WEGOVY	Anti-Obesity Agents	2	4	28.5	\$5,243	\$1,310.84	\$1.49	\$0.00	\$1.49	-	-	-
16	36	106	SOLIQUA 100/ 33	Insulin	1	2	90.0	\$4,970	\$2,485.08	\$1.41	\$0.62	\$0.08	127.4%	Utilzn	114.1%
17	19	656	HUMALOG MIX 50/ 50 KWIKPEN	Insulin	1	2	90.0	\$4,835	\$2,417.26	\$1.38	\$1.27	\$0.01	8.4%	Utilzn	7.1%
18	1	119	STRIBILD	HIV-Multiclass Combo	1	1	30.0	\$4,740	\$4,739.51	\$1.35	\$4.91	\$0.07	-72.5%	Utilzn	-78.6%
19	20	105	BYDUREON BCISE	GLP-1 Receptor Agonists	1	6	29.0	\$4,648	\$774.71	\$1.32	\$1.20	\$0.08	10.5%	Utilzn	7.1%
20	25	36	DEXCOM G6 SENSOR	Diabetes Monitoring and Testing Supplies	2	4	90.0	\$4,004	\$1,001.05	\$1.14	\$1.00	\$0.32	14.5%	Utilzn	7.1%
Total					38	200	36.3	\$163,030	\$815.15	\$46.38	\$36.28	\$28.56	27.9%		41.6%
Plan Total					362	3,430	30.6	\$323,688	\$94.37	\$92.09	\$91.39	\$66.72	0.8%		2.2%

Top 20 specialty

All meds are Brands except indicated with a “G” for generic

Rank													Trend components		
Cu ↕	Pv ↕	Bench ↕	Drug name ↕	Therapy class ↕	Utiliz ↕	Rxs ↕	Avg days supply ↕	Total plan paid ↕	Plan paid per Rx ↕	Curr plan paid PMPM ↕	Prev plan paid PMPM ↕	Bench plan paid PMPM ↕	% Trend ↕	Top driver ↕	% Top driver ↕
1	1	3	DUPIXENT	Chronic Inflammatory Disease	3	20	28.0	\$65,361	\$3,268.03	\$18.59	\$10.44	\$3.08	78.1%	Utilizn	78.4%
2	2	1	HUMIRA PEN	Chronic Inflammatory Disease	1	6	28.0	\$42,775	\$7,129.14	\$12.17	\$10.00	\$8.88	21.7%	Cost	9.4%
3	-	4	SKYRIZI PEN	Chronic Inflammatory Disease	1	2	29.0	\$40,702	\$20,351.12	\$11.58	\$0.00	\$2.62	-	-	-
4	-	44	KISQALI	Oncology	1	2	28.0	\$33,769	\$16,884.35	\$9.61	\$0.00	\$0.22	-	-	-
5	-	14	IBRANCE	Oncology	1	2	28.0	\$31,090	\$15,545.22	\$8.85	\$0.00	\$0.71	-	-	-
6	-	202	TRIPTODUR	LHRH/GNRH Agonist/Antagonists	1	1	168.0	\$19,771	\$19,770.81	\$5.62	\$0.00	\$0.03	-	-	-
7	3	9	OTEZLA	Chronic Inflammatory Disease	1	2	30.0	\$9,465	\$4,732.70	\$2.69	\$1.05	\$1.28	157.2%	Cost	157.2%
8	-	5	TALTZ	Chronic Inflammatory Disease	1	1	28.0	\$6,940	\$6,940.24	\$1.97	\$0.00	\$2.02	-	-	-
9	4	191	MYCOPHENOLATE MOFETIL	Transplant G	1	3	90.0	\$4,415	\$1,471.57	\$1.26	\$0.78	\$0.04	60.6%	Utilizn	60.6%
10	5	187	TACROLIMUS	Transplant G	1	6	90.0	\$2,731	\$455.19	\$0.78	\$0.48	\$0.04	60.6%	Utilizn	60.6%
Total					9	45	43.6	\$257,019	\$5,711.54	\$73.12	\$22.76	\$19.72	221.3%		101.4%
Plan Total					9	45	43.6	\$257,019	\$5,711.54	\$73.12	\$22.76	\$59.62	221.3%		101.4%

5 out of the top 10 are for Chronic Inflammatory Disease

5 out of the top 10 have moved up in rank